The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
Sign in to access this content
Sign InIn a move reflecting accelerated growth within the legal cannabis sector, High Tide has issued optimistic guidance for its third fiscal quarter ending July 31, 2026. The company expects to report record revenue between C$195M and C$200M, driven by robust retail performance. According to reports, Adjusted EBITDA is projected to reach between C$15.2M and C$16.5M, significantly exceeding the analyst consensus of C$14.0M.
This positive outlook is partly attributed to international success, with the company announcing a record distribution of over 10 tonnes of medical cannabis flower in the German market via Remexian Pharma GmbH. Per market data, this volume represents a 60% year-over-year increase in Germany. These results come as the company continues to expand its footprint, currently holding approximately 12% of the Canadian bricks-and-mortar market share.
High Tide is scheduled to release its full financial and operational results for the third fiscal quarter after market close on September 14, 2026. Regarding the broader economic context, US CB Consumer Confidence data released on July 28, 2026, stood at 90.8, missing the 92.4 forecast, which underscores the importance of monitoring consumer spending power in the company's key markets moving forward.